Research programme: antibody therapeutics - Northern Biologics

Drug Profile

Research programme: antibody therapeutics - Northern Biologics

Alternative Names: NB 0893; NB 6253; NB 6377

Latest Information Update: 01 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University Health Network; University of Toronto
  • Developer Northern Biologics
  • Class Antibodies; Antineoplastics
  • Mechanism of Action Immunologic receptor modulators; Immunomodulators; Membrane protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Fibrosis

Most Recent Events

  • 29 Apr 2015 Northern Biologics and Celgene Corporation enter strategic collaboration for development of antibody therapeutics for Cancer and Fibrosis
  • 10 Dec 2014 Preclinical trials in Cancer in Canada (unspecified route)
  • 10 Dec 2014 Preclinical trials in Fibrosis in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top